Logo image of EDT.CA

SPECTRAL MEDICAL INC (EDT.CA) Stock Fundamental Analysis

TSX:EDT - Toronto Stock Exchange - CA8475771033 - Common Stock - Currency: CAD

0.65  +0.01 (+1.56%)

Fundamental Rating

1

Overall EDT gets a fundamental rating of 1 out of 10. We evaluated EDT against 25 industry peers in the Biotechnology industry. EDT has a bad profitability rating. Also its financial health evaluation is rather negative. EDT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EDT has reported negative net income.
In the past year EDT has reported a negative cash flow from operations.
In the past 5 years EDT always reported negative net income.
EDT had a negative operating cash flow in each of the past 5 years.
EDT.CA Yearly Net Income VS EBIT VS OCF VS FCFEDT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

EDT has a worse Return On Assets (-305.54%) than 65.00% of its industry peers.
Industry RankSector Rank
ROA -305.54%
ROE N/A
ROIC N/A
ROA(3y)-156.78%
ROA(5y)-140.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EDT.CA Yearly ROA, ROE, ROICEDT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

EDT's Gross Margin of 39.78% is fine compared to the rest of the industry. EDT outperforms 65.00% of its industry peers.
EDT's Gross Margin has declined in the last couple of years.
EDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.04%
GM growth 5Y-14.44%
EDT.CA Yearly Profit, Operating, Gross MarginsEDT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

EDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EDT has about the same amount of shares outstanding.
Compared to 5 years ago, EDT has more shares outstanding
EDT has a worse debt/assets ratio than last year.
EDT.CA Yearly Shares OutstandingEDT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
EDT.CA Yearly Total Debt VS Total AssetsEDT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -30.53, we must say that EDT is in the distress zone and has some risk of bankruptcy.
EDT has a Altman-Z score (-30.53) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -30.53
ROIC/WACCN/A
WACC8.14%
EDT.CA Yearly LT Debt VS Equity VS FCFEDT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M -15M

2.3 Liquidity

A Current Ratio of 0.22 indicates that EDT may have some problems paying its short term obligations.
With a Current ratio value of 0.22, EDT is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
EDT has a Quick Ratio of 0.22. This is a bad value and indicates that EDT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.21, EDT is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.22
Quick Ratio 0.21
EDT.CA Yearly Current Assets VS Current LiabilitesEDT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for EDT have decreased strongly by -42.70% in the last year.
Looking at the last year, EDT shows a quite strong growth in Revenue. The Revenue has grown by 13.98% in the last year.
Measured over the past years, EDT shows a very negative growth in Revenue. The Revenue has been decreasing by -16.08% on average per year.
EPS 1Y (TTM)-42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-254.8%
Revenue 1Y (TTM)13.98%
Revenue growth 3Y-8.7%
Revenue growth 5Y-16.08%
Sales Q2Q%26.45%

3.2 Future

The Earnings Per Share is expected to grow by 21.21% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 18.82% on average over the next years. This is quite good.
EPS Next Y-23.87%
EPS Next 2Y21.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.53%
Revenue Next 2Y18.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EDT.CA Yearly Revenue VS EstimatesEDT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
EDT.CA Yearly EPS VS EstimatesEDT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.02 -0.04 -0.06 -0.08

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EDT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDT.CA Price Earnings VS Forward Price EarningsEDT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDT.CA Per share dataEDT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08 -0.1

4.3 Compensation for Growth

EDT's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EDT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPECTRAL MEDICAL INC

TSX:EDT (2/21/2025, 7:00:00 PM)

0.65

+0.01 (+1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners0.04%
Inst Owner ChangeN/A
Ins Owners1.4%
Ins Owner ChangeN/A
Market Cap185.09M
Analysts84
Price Target2.04 (213.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-40%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)40%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -305.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.78%
FCFM N/A
ROA(3y)-156.78%
ROA(5y)-140.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.04%
GM growth 5Y-14.44%
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.5%
Cap/Sales 10.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.22
Quick Ratio 0.21
Altman-Z -30.53
F-Score3
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)85.19%
Cap/Depr(5y)83.19%
Cap/Sales(3y)12.26%
Cap/Sales(5y)11.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-254.8%
EPS Next Y-23.87%
EPS Next 2Y21.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.98%
Revenue growth 3Y-8.7%
Revenue growth 5Y-16.08%
Sales Q2Q%26.45%
Revenue Next Year23.53%
Revenue Next 2Y18.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.12%
OCF growth 3YN/A
OCF growth 5YN/A